Bone fragility has traditionally been associated with osteoporosis and reduced bone mineral density; however, contemporary evidence indicates that fracture risk is influenced by a broader spectrum of metabolic, nutritional, endocrine, inflammatory, and musculoskeletal factors. The objective of this review was to analyze the metabolic determinants associated with bone fragility beyond osteoporosis and to examine their influence on fracture risk and recovery outcomes. A structured narrative review of scientific literature published in major biomedical databases was conducted, focusing on diabetes mellitus, chronic kidney disease, vitamin D deficiency, malnutrition, osteosarcopenia, endocrine dysfunction, and chronic inflammation. The findings demonstrated that these conditions contribute significantly to alterations in bone quality, remodeling capacity, muscle performance, and tissue repair, thereby increasing susceptibility to fragility fractures independently of bone mineral density measurements. Diabetes mellitus and chronic kidney disease emerged as major determinants of skeletal fragility due to their effects on collagen integrity, mineral metabolism, vascular function, and bone turnover. Nutritional deficiencies and inadequate vitamin D status were consistently associated with impaired mineralization, increased fall risk, and delayed fracture healing. Furthermore, osteosarcopenia highlighted the close biological relationship between bone and muscle health and its contribution to fracture susceptibility and functional decline. The evidence supports a multidimensional understanding of skeletal fragility that incorporates metabolic health into fracture prevention and management strategies. Expanding fracture risk assessment beyond traditional osteoporosis models may improve early identification of vulnerable individuals and facilitate more comprehensive approaches to prevention, treatment, and rehabilitation.
A practical clinical framework is proposed that integrates endocrine phenotype, vertebral imaging, trabecular bone score, and biochemical assessment into fracture-risk stratification and therapeutic decision-making, enabling improved identification of high- and very-high-risk patients and facilitating the appropriate use of anabolic and antiresorptive therapies.
I. Cincione, Robert A. Marcantonio, Marcellino Monda et al.· Frontiers in Endocrinology· 0 citations
This Perspective proposes a bone–muscle–function framework to complement existing osteoporosis-centered approaches to fragility fracture prevention and organizes bone, muscle, and function into a staged framework for risk identification, recovery planning, and secondary prevention.
Shengzhu Lu, Chaodong Liu, Yinyao Gou et al.· Frontiers in Medicine· 0 citations
Current clinical and biological evidence on the interactions among obesity, skeletal muscle, and bone is summarized, and the implications of these relationships for integrated lifestyle-based interventions aimed at preserving musculoskeletal integrity and metabolic health across the lifespan are discussed.
Olivia Di Vincenzo, Ludovica Cardinali, Marianna Minnetti et al.· International Journal of Bon...· 0 citations
The need to move beyond BMD alone and adopt comprehensive, individualized approaches to fracture risk assessment and management in obesity is highlighted.
Riad Sulimani· Frontiers in Endocrinology· 0 citations
Results indicate that radiofrequency echographic multispectrometry provides BMD and fracture risk assessment comparable to DXA in patients on peritoneal dialysis, while also highlighting the impact of vascular calcifications on the diagnostic accuracy of lumbar spine DXA measurements.
O. Nishkumay, O. Iaremenko, V.E. Kondratiuk et al.· International Journal of End...· 0 citations
Therapeutic management becomes increasingly complex in advanced CKD, where fracture risk is high, and evidence for osteoporosis treatments is limited, and evidence for osteoporosis treatments is limited.
Giuseppe Cianciolo, Antonio Bellasi, Sandro Giannini et al.· Kidney360· 0 citations